Amsterdam 2013 Programme Satellite Meetings Registration Exhibition Virtual Exhibition Hotels Visa Letter Invitation
Search Abstracts by author or title
(results will display both Free Papers & Poster)
Back to Freepaper Session

enVista toric: insights from early experience

Session Details

Session Title: Toric IOL Outcomes

Session Date/Time: Monday 07/10/2013 | 16:30-18:30

Paper Time: 17:33

Venue: Auditorium (First Floor)

First Author: : O.Moraru ROMANIA

Co Author(s): :    I. Iliescu              

Abstract Details


To present the clinical outcomes in a group of patients operated for cataract with implantion of a new hydrophobic toric intraocular lens (IOL). The rotational stability of the lens was also followed.


Oculus Eye Clinic – Bucharest – Romania


This prospective cohort consisted of 18 eyes with medium or advanced cataract and a moderate corneal astigmatism less than 2.0D. After Coaxial Microincision Cataract Surgery (C-MICS), an enVista® toric (Model MX60T) intraocular lens was implanted in the capsular bag. Three toric cylinder powers were evaluated: 1.25D, 2.00D and 2.75 D (IOL plane). The postoperative distance uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), objective and subjective (manifest) refraction, spectacle independence and IOL axis alignment were measured at 1 month. A further 3 months follow-up will also be evaluated.


The study includes 18 eyes with 1 Month follow-up with preoperative corneal astigmatism from 0.75D to 1.75D. 100% of eyes achieved a postoperative UCVA of 20/40 or better and 87% of 20/30 or better. The postoperative BCVA was 20/25 or better in 93.3% of eyes. The postoperative subjective refractive cylinder was 0.5 D or less in 80% of eyes which shows a high postoperative spectacle independence for distance vision. IOL axis rotation was 5° or less in all eyes with 80% of the eyes with 2 degrees or less of IOL rotation. No complications occurred.


Our results show that the implantation of the enVista® toric IOL is a safe and effective procedure to correct moderate corneal astigmatism in cataract patients.

Financial Interest:

... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

loading Please wait while information is loading.